Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
BTCT - BTC Digital Ltd - Stock Price Chart
TickerBTCT [NASD]
CompanyBTC Digital Ltd
CountryChina
IndustryComputer Hardware
Market Cap27.42MEPS (ttm)-1.89
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y94.08%
P/S3.02EPS next 5Y-
P/B1.40EPS Q/Q92.25%
Dividend-Sales Q/Q-92.66%
Insider Own24.38%Inst Own1.35%
Insider Trans0.00%Inst Trans105.95%
Short Float0.65%EarningsAug 21
Analyst Recom1.00Target Price3.00
Avg Volume67.58K52W Range1.32 - 6.06
BTC Digital Ltd. is a blockchain technology company, with a long-term strategy to create value across the metaverse, blockchain and cryptocurrency mining industry. The company was founded in April 2006 and is headquartered in Shenzhen, China.
NA - Nano Labs Ltd - Stock Price Chart
TickerNA [NASD]
CompanyNano Labs Ltd
CountryChina
IndustrySemiconductors
Market Cap576.42MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own87.28%Inst Own0.03%
Insider Trans0.00%Inst Trans-
Short Float0.19%EarningsSep 18/b
Analyst Recom-Target Price-
Avg Volume53.52K52W Range2.75 - 47.50
Nano Labs Ltd. is a holding company, which engages in design and provision of product solution of fabless integrated circuit. It offers high throughput computing chips, high performance computing chips, distributed computing and storage solutions, smart network interface cards, vision computing chips, and distributed rendering. The company was founded in July 2019 and is headquartered in Hangzhou, China.
NXTT - Next Technology Holding Inc - Stock Price Chart
TickerNXTT [NASD]
CompanyNext Technology Holding Inc
CountryChina
IndustrySoftware - Application
Market Cap14.16MEPS (ttm)7.99
P/E0.25EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-122.12%
P/S5.38EPS next 5Y-
P/B0.19EPS Q/Q-496550.00%
Dividend-Sales Q/Q-
Insider Own17.33%Inst Own0.58%
Insider Trans0.00%Inst Trans22.73%
Short Float0.13%Earnings-
Analyst Recom-Target Price-
Avg Volume25.75K52W Range0.94 - 10.03
Next Technology Holding, Inc. engages in the provision of software development services to the customers and bitcoin acquisition. The company was founded on March 28, 2019 and is headquartered in Shenzhen, China.
MULN - Mullen Automotive Inc - Stock Price Chart
TickerMULN [NASD]
CompanyMullen Automotive Inc
CountryUSA
IndustryAuto Manufacturers
Market Cap16.57MEPS (ttm)-10260.49
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y44.05%
P/S103.58EPS next 5Y-
P/B0.01EPS Q/Q99.29%
Dividend-Sales Q/Q-78.82%
Insider Own5.50%Inst Own1.36%
Insider Trans-7.54%Inst Trans375.83%
Short Float20.77%EarningsMay 14/a
Analyst Recom-Target Price51750000.00
Avg Volume1.61M52W Range1.60 - 2250.00
Mullen Automotive Inc. operates as an electric vehicle company, which engages in the manufacture of passenger electric vehicles and commercial vehicles. It operates through the Bollinger and Mullen/ELMS segments. The company was founded by David Michery on April 20, 2010 and is headquartered in Brea, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
POPA CALINPresident - Mullen AutomotiveJun 06 '24Sale3.1023,22371,991286,506Jun 12 08:00 PM
POPA CALINPresident - Mullen AutomotiveJun 07 '24Sale3.091,7225,321284,784Jun 12 08:00 PM
GNS - Genius Group Ltd - Stock Price Chart
TickerGNS [AMEX]
CompanyGenius Group Ltd
CountrySingapore
IndustryEducation & Training Services
Market Cap22.80MEPS (ttm)-0.25
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-15.99%
P/S0.99EPS next 5Y-
P/B5.53EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own4.49%Inst Own0.74%
Insider Trans0.00%Inst Trans-21.88%
Short Float7.02%EarningsMay 16/b
Analyst Recom-Target Price50.00
Avg Volume696.38K52W Range0.51 - 9.49
Genius Group Ltd. engages in developing artificial intelligence education. It offers educational, entrepreneurship, business, psychometric tests, and entrepreneur education platform. Its brands include GeniusGroup, geniusU, openexo, Education Angels, E-Square Education, pin, FatBrAin, and Revealed Films. It operates through the Education and Campus segments. The Education segment refers to entrepreneur education, management, and business development tools. The Campus segment includes resorts, retreats, and co-working cafes for entrepreneurs. The company was founded by Roger James Hamilton on November 30, 2015 and is headquartered in Singapore.
AGFY - Agrify Corp - Stock Price Chart
TickerAGFY [NASD]
CompanyAgrify Corp
CountryUSA
IndustryFarm & Heavy Construction Machinery
Market Cap10.20MEPS (ttm)-12.53
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-4.60%
P/S0.88EPS next 5Y20.00%
P/B0.88EPS Q/Q96.75%
Dividend-Sales Q/Q-40.90%
Insider Own0.00%Inst Own2.36%
Insider Trans-Inst Trans162.79%
Short Float2.06%Earnings-
Analyst Recom1.00Target Price900.00
Avg Volume371.25K52W Range2.71 - 42.00
Agrify Corp. engages in the development of hardware and software solutions for indoor agriculture. The company was founded on June 6, 2016 and is headquartered in Troy, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chang Raymond NobuCEO and ChairmanFeb 28 '24Buy0.381,842,104700,0003,295,998Mar 01 04:30 PM
GNPX - Genprex Inc - Stock Price Chart
TickerGNPX [NASD]
CompanyGenprex Inc
CountryUSA
IndustryBiotechnology
Market Cap5.41MEPS (ttm)-16.05
P/E-EPS this Y75.40%
Forward P/E-EPS next Y70.27%
PEG-EPS past 5Y8.89%
P/S-EPS next 5Y-
P/B1.23EPS Q/Q51.07%
Dividend-Sales Q/Q-
Insider Own6.26%Inst Own10.49%
Insider Trans0.00%Inst Trans-
Short Float14.95%EarningsAug 28
Analyst Recom1.00Target Price7.50
Avg Volume8.98M52W Range0.28 - 14.40
Nov-05-24 09:29AM Genprex Collaborators Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire) -10.40%
Oct-31-24 09:29AM Genprex to Participate in 2024 BIO Europe Conference (PR Newswire) +11.39%
Oct-28-24 09:29AM Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma (PR Newswire) +38.38%
Oct-24-24 09:29AM Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive (PR Newswire) -19.25%
Oct-16-24 07:45AM Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa (Clinical Trials Arena)
Oct-15-24 09:29AM Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer (PR Newswire)
Oct-10-24 09:29AM Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-07-24 09:29AM Genprex Collaborators to Present Positive Preclinical Data on Reqorsa Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting (PR Newswire)
Sep-23-24 09:29AM Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes (PR Newswire) +8.85%
Sep-19-24 09:29AM Genprex Announces Formation of Mesothelioma Clinical Advisory Board (PR Newswire) +6.85%
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company's lead product candidate is REQORSA immunogene therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.
BTCS - BTCS Inc - Stock Price Chart
TickerBTCS [NASD]
CompanyBTCS Inc
CountryUSA
IndustryCapital Markets
Market Cap47.67MEPS (ttm)0.87
P/E3.31EPS this Y-61.82%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S29.98EPS next 5Y-
P/B1.50EPS Q/Q-481.74%
Dividend-Sales Q/Q45.48%
Insider Own44.37%Inst Own4.05%
Insider Trans-0.34%Inst Trans14.19%
Short Float0.72%EarningsAug 20/b
Analyst Recom1.00Target Price3.00
Avg Volume115.48K52W Range0.95 - 2.50
BTCS, Inc. engages in the digital currency ecosystem and blockchain technologies. It manages an online marketplace where consumers can purchase merchandise using digital currencies such as bitcoin. The company was founded by Timothy Sidie and Michal Handerhan in 2008 and is headquartered in Silver Spring, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pump MelanieDirectorJun 05 '24Sale1.5614,99823,39737,414Jun 06 04:05 PM
Pump MelanieDirectorJun 06 '24Sale1.556,64110,29430,773Jun 06 04:05 PM
Pump MelanieDirectorJun 04 '24Sale1.603,3615,37852,412Jun 06 04:05 PM
Handerhan MichalCOOMar 08 '24Sale1.5269,453105,7071,613,878Mar 11 04:01 PM
Handerhan MichalCOOMar 07 '24Sale1.5128,16542,6191,683,331Mar 11 04:01 PM
KAPA - Kairos Pharma Ltd - Stock Price Chart
TickerKAPA [AMEX]
CompanyKairos Pharma Ltd
CountryUSA
IndustryBiotechnology
Market Cap26.38MEPS (ttm)-0.16
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-7.07%
Dividend-Sales Q/Q-
Insider Own52.17%Inst Own-
Insider Trans0.00%Inst Trans-
Short Float0.11%EarningsAug 28
Analyst Recom1.00Target Price9.00
Avg Volume140.88K52W Range1.22 - 4.00
Kairos Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of novel and transformative drug therapies to treat cancer. It focuses on the research and development of immunotherapies for oncology. The company was founded by John S. Yu on June 17, 2013 and is headquartered in Los Angeles, CA.
MNOV - Medicinova Inc - Stock Price Chart
TickerMNOV [NASD]
CompanyMedicinova Inc
CountryUSA
IndustryBiotechnology
Market Cap111.82MEPS (ttm)-0.17
P/E-EPS this Y-35.29%
Forward P/E-EPS next Y-4.35%
PEG-EPS past 5Y13.30%
P/S111.82EPS next 5Y20.00%
P/B1.95EPS Q/Q8.53%
Dividend-Sales Q/Q-
Insider Own5.24%Inst Own18.72%
Insider Trans0.00%Inst Trans-0.55%
Short Float0.39%EarningsAug 08/a
Analyst Recom1.00Target Price10.00
Avg Volume39.29K52W Range1.12 - 2.16
Nov-11-24 06:00PM MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis (GlobeNewswire) +49.02%
Oct-23-24 07:00PM MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) (GlobeNewswire)
Sep-30-24 09:00AM MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +9.95%
Sep-09-24 07:00PM MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND (GlobeNewswire) -9.05%
Sep-03-24 07:00PM MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting (GlobeNewswire) +10.00% +7.27%
Aug-29-24 07:00PM MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition (GlobeNewswire) +14.50%
Jun-20-24 06:00AM MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations (GlobeNewswire)
Jun-05-24 06:00AM MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer (GlobeNewswire)
Jun-03-24 06:00AM MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 (GlobeNewswire) +8.09%
May-28-24 06:00AM MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions (GlobeNewswire)
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.
1234561020